Novartis cholesterol setback tests hopes for emerging heart disease drugs
Novartis shares decline after its cholesterol drug pelacarsen failed a critical late-stage cardiovascular trial, impacting expectations for heart disease treatments.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Novartis shares fell following a second pipeline setback of the week after its pelacarsen heart drug missed its target in a late-stage trial. The failed cardiovascular test cast doubt over a multibillion-dollar race and tested hopes for emerging heart disease drugs.
Subsequent coverage quieted without a definitive conclusion regarding the broader outlook for the treatment class.
Epilogue added 68d ago, after coverage quieted.
The brief
Novartis is facing a significant clinical setback as its cholesterol-lowering drug, pelacarsen, failed a critical cardiovascular test. This failure occurred during a late-stage trial designed to evaluate the drug's effectiveness in treating heart disease. The results of this specific trial have led to immediate market reactions, as the company's strategic goals for this particular therapeutic candidate were not met. The failure is a direct hit to the development pipeline for heart disease treatments currently being managed by the pharmaceutical firm. Financial and industry reporting on the event is widespread, with major outlets documenting the fallout. The Wall Street Journal reports that Novartis shares fell following the news that the heart drug missed its target in the late-stage trial.
Simultaneously, Reuters has framed the event as a setback that tests the broader hopes for emerging heart disease drugs. First Word Pharma provided specific technical details, confirming that pelacarsen failed the critical cardiovascular test, highlighting the clinical nature of the disappointment. This development is significant because it affects the trajectory of emerging heart disease therapies. The focus on pelacarsen was tied to the broader goal of creating more effective ways to manage cholesterol and reduce cardiovascular risks. Because this was a late-stage trial, the drug had already passed through several earlier phases of testing, making this specific failure a critical blow to the likelihood of the drug reaching the market. The current market volatility reflects investor concerns over the viability of this specific pharmacological approach.
Future attention will be focused on how Novartis manages its remaining cardiovascular portfolio after this miss. Investors and medical analysts will be monitoring the company for updates on other heart disease candidates. While the coverage does not yet specify the exact next steps for pelacarsen, the focus remains on whether this setback indicates a wider issue for similar emerging heart disease drugs. The industry will be watching to see if Novartis pivots its strategy or continues to pursue related cholesterol-lowering mechanisms in subsequent trials.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 71d ago.
Quick answers
What drug failed the trial?
The drug is called pelacarsen, developed by Novartis.
How did the market react to the news?
According to the Wall Street Journal, Novartis shares fell after the heart drug missed its target.
At what stage was the trial?
The failure occurred during a late-stage trial.
Who reported on the setback?
The event was reported by the Wall Street Journal, Reuters, and First Word Pharma.
Coverage (5)
- Novartis shares sink on second pipeline setback this week Reuters · 71d ago
- Cholesterol drug setback casts doubt over multibillion-dollar race CNBC · 71d ago
- Novartis' pelacarsen fails critical cardiovascular test firstwordpharma.com · 71d ago
- Novartis Shares Fall After Heart Drug Misses Target in Late-Stage Trial WSJ · 71d ago
- Novartis cholesterol setback tests hopes for emerging heart disease drugs Reuters · 71d ago
Topics
Related trends
The first pill to slow Alzheimer’s could come from an unexpected place
An experimental oral Alzheimer's drug derived from an unexpected medical category shows varied results in phase 3 clinical trials.
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche wins FDA approval for its first U.S. oral SERD, giredestrant plus everolimus, for hormone-resistant advanced breast cancer.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
Experts spell out what heart health means for women of all ages
New joint heart health guidance from the American Heart Association and three other medical groups urges cardiovascular screening for women at every life stage.
Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug
A former Eli Lilly sales representative has filed a retaliation lawsuit alleging she was fired for objecting to Mounjaro marketing.
Column | Your stroke risk is 72 percent higher during these 3 hours of the day
Multiple outlets report stroke risk spikes 72 percent higher during a specific three-hour morning window, citing new medical research.